Literature DB >> 12359827

New concepts in the treatment of rheumatoid arthritis.

Raphaela Goldbach-Mansky1, Peter E Lipsky.   

Abstract

Recent advances have made rheumatoid arthritis (RA) amenable to treatment. Clinical studies in patients with early and established RA have broadened understanding of its pathogenesis and have fundamentally changed the therapeutic approach to this disease. Quantum leaps in therapy-including the use of early, aggressive therapy, combination therapy, and the introduction of anti-cytokine agents-have improved patients' quality of life, eased clinical symptoms, retarded the progression of joint destruction, and delayed disability. We review clinical evidence supporting these therapeutic approaches. Diagnostic and therapeutic challenges are highlighted, and a decision tree to guide treatment in patients with early or established RA is provided.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12359827     DOI: 10.1146/annurev.med.54.101601.152342

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  10 in total

1.  Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis.

Authors:  Je-Min Choi; Seung-Hyung Kim; Jae-Hoon Shin; Thomas Gibson; Byoung-Seok Yoon; Dong-Ho Lee; Seung-Kyou Lee; Alfred L M Bothwell; Jong-Soon Lim; Sang-Kyou Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-09       Impact factor: 11.205

2.  A novel small-molecule tumor necrosis factor α inhibitor attenuates inflammation in a hepatitis mouse model.

Authors:  Li Ma; Haiyan Gong; Haiyan Zhu; Qing Ji; Pei Su; Peng Liu; Shannan Cao; Jianfeng Yao; Linlin Jiang; Mingzhe Han; Xiaotong Ma; Dongsheng Xiong; Hongbo R Luo; Fei Wang; Jiaxi Zhou; Yuanfu Xu
Journal:  J Biol Chem       Date:  2014-03-14       Impact factor: 5.157

3.  Expression and purification of a natural N-terminal pre-ligand assembly domain of tumor necrosis factor receptor 1 (TNFR1 PLAD) and preliminary activity determination.

Authors:  Jin Cao; Fang Meng; Xiangdong Gao; Hongxia Dong; Wenbing Yao
Journal:  Protein J       Date:  2011-04       Impact factor: 2.371

4.  Pharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugates in adjuvant-induced arthritis rat model.

Authors:  Ling-Dong Quan; Fang Yuan; Xin-Ming Liu; Jian-Geng Huang; Yazen Alnouti; Dong Wang
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

Review 5.  Pathogenesis of Graves' orbitopathy: a 2010 update.

Authors:  T J Smith
Journal:  J Endocrinol Invest       Date:  2010-06       Impact factor: 4.256

6.  Occupations and exposures in the work environment as determinants for rheumatoid arthritis.

Authors:  A Reckner Olsson; T Skogh; O Axelson; G Wingren
Journal:  Occup Environ Med       Date:  2004-03       Impact factor: 4.402

Review 7.  Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis.

Authors:  Patricia Guyot; Peter Taylor; Robin Christensen; Louisa Pericleous; Coralie Poncet; Maximilian Lebmeier; Pieter Drost; Gert Bergman
Journal:  Arthritis Res Ther       Date:  2011-12-12       Impact factor: 5.156

8.  Antioxidant and angiostatic effect of Spirulina platensis suspension in complete Freund's adjuvant-induced arthritis in rats.

Authors:  Eman A I Ali; Bassant M Barakat; Ranya Hassan
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

9.  Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis.

Authors:  Michihito Sato; Kumiko Ohtsuka; Ryo Takahashi; Kuninobu Wakabayashi; Tsuyoshi Odai; Takeo Isozaki; Nobuyuki Yajima; Yusuke Miwa; Tsuyoshi Kasama
Journal:  Open Access Rheumatol       Date:  2011-01-07

10.  RGD(F/S/V)-Dex: towards the development of novel, effective, and safe glucocorticoids.

Authors:  Xueyun Jiang; Ming Zhao; Yuji Wang; Haimei Zhu; Shurui Zhao; Jianhui Wu; Yuanbo Song; Shiqi Peng
Journal:  Drug Des Devel Ther       Date:  2016-03-08       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.